Fig. 2: Kaplan–Meier estimates of NEDA, and freedom from relapse, new MRI events and CDW. | Bone Marrow Transplantation

Fig. 2: Kaplan–Meier estimates of NEDA, and freedom from relapse, new MRI events and CDW.

From: BEAM or cyclophosphamide in autologous haematopoietic stem cell transplantation for relapsing-remitting multiple sclerosis

Fig. 2

Kaplan–Meier estimates of maintaining the composite endpoint no evidence of disease activity (NEDA), including the Kaplan–Meier estimates of the individual parts of NEDA: freedom from new MRI events, freedom from relapse and freedom from confirmed disease worsening (CDW) after autologous haematopoietic stem cell transplantation (ASCT) up to 5 years of follow-up.

Back to article page